Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 602.

https://doi.org/10.1182/blood-2019-130644

Published: 2019

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Swetha Kambhampati, MD, Derek Galligan, MD, Guy Ledergor, MD, Thomas G. Martin, III, MD, Jeffrey Wolf, Sandy W. Wong, Nina D. Shah, MD

Blood (2019) 134 (Supplement_1): 5576.

https://doi.org/10.1182/blood-2019-122383

Published: 2019

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Germline Variation Predicts Treatment Response in Multiple Myeloma

Kyle Roter, BSc, Donglei Hu, PhD, Alyssa Clay-Gilmour, PhD, Scott Huntsman, Nina D. Shah, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD, Moritz Binder, MDMPH, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Celine M. Vachon, PhD, Elad Ziv, MD

Blood (2019) 134 (Supplement_1): 4397.

https://doi.org/10.1182/blood-2019-129344

Published: 2019

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD

Blood (2019) 134 (Supplement_1): 3145.

https://doi.org/10.1182/blood-2019-130410

Published: 2019

Journal Articles

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Derek Galligan, MD, Rupa Narayan, MD, Sarah Kim, PharmD, Ann Lazar, PhD MS, Marisela Tan, PharmD, Richard Fong, PharmD, Mimi Lo, PharmD, Nina Shah, MD, Shagun Arora, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD

Blood (2018) 132 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2018-99-111625

Published: 2018

Journal Articles

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Li-Wen Huang, MD, Chiung-Yu Huang, PhD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Catherine C. Smith, MD, Karin M. Gaensler, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Michael A. Steinman, MD, Rebecca L. Olin, MD

Blood (2018) 132 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2018-99-112025

Published: 2018

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

Ravi Vij, MBBS, Nitya Nathwani, MD, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L Kaufman, MD, Craig C Hofmeister, MDMPH, Tara Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2018) 132 (Supplement 1): 123.

https://doi.org/10.1182/blood-2018-99-109920

Published: 2018

Journal Articles

The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Gabriel N. Mannis, MD, Nicole Therrien, Jessica Van Ziffle, Nicole Foley, Iwei Yeh, Shan Zhong, PhD, Jie He, PhD, Michelle Nahas, PhD, Charalambos Andreadis, MD MSCE, Lloyd E. Damon, MD, Rebecca L. Olin, MD MS, Sonam Prakash, MD, Tariq I Mughal, MD FRCP, Aaron C. Logan, MDPhDMPhil, Thomas G. Martin, III, MD

Blood (2017) 130 (Supplement 1): 1423.

https://doi.org/10.1182/blood.V130.Suppl_1.1423.1423

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey Zonder, MD, Thomas G. Martin, III, MD, Emma C. Scott, MD, Janice Chen, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Claudia E. Paba-Prada, MD

Blood (2016) 128 (22): 5696.

https://doi.org/10.1182/blood.V128.22.5696.5696

Published: 2016

Journal Articles

Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients

Jeffrey L. Wolf, MD, Katherine A. Kong, PhD, Jenai Wilmoth, RN, Joshua Bayes, Amy Marsala, ANP,MPH, Victoria Carlton, PhD, Aaron Logan, MDPhD, Thomas G. Martin, III, MD

Blood (2016) 128 (22): 3286.

https://doi.org/10.1182/blood.V128.22.3286.3286

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)

Bradley Hunter, MD MPH, Ben Rosen, MD, Miguel Castillo, Lawrence D. Kaplan, MD, Weiyun Z. Ai, MD PhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, Charalambos Andreadis, MD MSCE

Blood (2016) 128 (22): 4638.

https://doi.org/10.1182/blood.V128.22.4638.4638

Published: 2016

Journal Articles

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Gabriel N. Mannis, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Charalambos Andreadis, MD MSCE, Rebecca L. Olin, MD MSCE, Katie Kong, Malek Faham, MD PhD, Weiyun Z. Ai, MD PhD, Karin ML Gaensler, MD, Peter H. Sayre, MD PhD, Jeffrey L. Wolf, MD PhD, Aaron C. Logan, MD PhD

Blood (2015) 126 (23): 1420.

https://doi.org/10.1182/blood.V126.23.1420.1420

Published: 2015

Journal Articles

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Matthew J. Wieduwilt, MD PhD, Scott Thomas, PhD, Rebecca L. Olin, MD MSCE, Aaron C. Logan, MDPhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, McNancy Kang, Peter H. Sayre, MD PhD, Wanda Boyer, NP,MSN, Karin ML Gaensler, MD, Kirsten Anderson, Pamela Munster, MD, Charalambos Andreadis, MD MSCE

Blood (2015) 126 (23): 1337.

https://doi.org/10.1182/blood.V126.23.1337.1337

Published: 2015

Journal Articles

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc., Eugen Dhimolea, PhD, Ruojing Li, BS, Megan A. Bariteau, BSc, Diamond D. Wheeler, BS, Rosemary J. Akhurst, PhD, Aaron C. Logan, MD PhD, Pamela Munster, MD, Arun Wiita, MD PhD, Thomas G. Martin, III, MD, Jeffrey L. Wolf, MD PhD, Jun O. Liu, PhD, Constantine S. Mitsiades, MD PhD, Blake T. Aftab, PhD

Blood (2015) 126 (23): 503.

https://doi.org/10.1182/blood.V126.23.503.503

Published: 2015

NARROW

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Germline Variation Predicts Treatment Response in Multiple Myeloma

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only